A Comprehensive Review on Anti-Viral Drugs

Antiviral drugs constitute a vital and rapidly evolving class of medications specifically designed to treat viral infections by interfering with distinct stages of the viral life cycle, such as attachment, replication, or release, while minimizing harm to the host organism. Unlike broad-spectrum antibiotics, most antivirals exhibit high specificity for a single virus or family, reflecting the challenge of targeting intracellular pathogens. This review article provides a comprehensive overview of the current landscape of antiviral therapy, detailing classification based on mechanism of action—including entry inhibitors, polymerase/reverse transcriptase inhibitors (e.g., acyclovir, tenofovir), protease inhibitors (e.g., ritonavir, atazanavir), integrase inhibitors (e.g., dolutegravir), and neuraminidase inhibitors (e.g., oseltamivir). It highlights significant clinical successes, such as highly active antiretroviral therapy (HAART) for HIV/AIDS and direct-acting antivirals for Hepatitis C, which have transformed previously fatal diseases into manageable or curable conditions. Furthermore, the abstract addresses the primary challenges facing the field, notably the rapid emergence of drug resistance due to high viral mutation rates, the need for stringent patient adherence, and the ongoing demand for broad-spectrum agents capable of addressing emerging pandemics. The conclusion emphasizes the continuous scientific endeavor to develop more effective, less toxic, and durable antiviral strategies, underscoring their indispensable role in modern public health alongside vaccination efforts.